By proceeding, you agree to our Terms of Use and Privacy Policy.
Frédéric Triebel, MD Ph.D. founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A in December 2014.
Talks About #marketing
Preferred Locations #Europe
With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine.
